Glycomacropeptide + Verteporfin
Verteporfin brand name: Visudyne.
We found no known interaction between Glycomacropeptide and Verteporfin in our sources. Absence of a documented interaction is not the same as proven safety, and does not guarantee one does not exist. Do not start, stop, or change a medication or supplement based on this page; confirm with your pharmacist or doctor first. Additionally, although there is no interaction, the two are separately associated with some of the same side effects, which would make a new symptom harder to attribute to one or the other.
Glycomacropeptide and Verteporfin
We checked these two against our interaction database. Here is what we found.
No Known Interaction Found
We did not find a documented interaction between Verteporfin and Glycomacropeptide in our sources. This does not guarantee that the combination is completely free of risk — there is often limited research on supplements and herbal products, especially around drug interactions.
Worth understanding: our licensed dataset holds no drug-interaction record for Glycomacropeptide at all — not against Verteporfin, and not against any other medication we track. This verdict therefore rests on the absence of any recorded data, not on research that looked at this combination and found nothing. We cannot rule an interaction out.
If you decide to take both, the practical routine is simple: add one new thing at a time and note the date you started it. If the combination is going to disagree with you, it usually shows in the first days to a couple of weeks — and a start date turns “I’ve been feeling off” into something a pharmacist can actually work with. Do not stop a prescribed medicine on your own.
Always talk with your pharmacist or doctor before making changes to your medications or supplements, particularly if you take several medications or have an ongoing health condition.
Glycomacropeptide safety at a glance
Safety guidance is general; always confirm with your pharmacist or doctor for your situation.
See Every Supplement That Interacts With Verteporfin
This page covers Glycomacropeptide only. If you take other supplements — a multivitamin, a sleep aid, something for joints — the Verteporfin page lists 18 supplements it has a documented interaction with, worst first, each one explained.
The most serious there right now: Activated Charcoal (major), Coffee Charcoal (moderate), Dimethylsulfoxide (dmso) (moderate), European Mandrake (moderate) and Glucomannan (moderate).
By severity: 1 major · 8 moderate · 9 minor.
From our pharmacist’s overview on the Verteporfin page
“Verteporfin (Visudyne) is infused into a vein, then activated with a laser to seal leaky blood vessels in the eye, and one entry here warrants real caution. Activated charcoal, the only major-rated interaction of the 18 on file, can strip many drugs from the body even when they were never swallowed, so I would not use it around a treat…”
Reviewed by 2 · Jul 18, 2026
Where Glycomacropeptide and Verteporfin Sit Against Everything Else
Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.
#1,189 of 1,452 supplements looked up here in the last 7 days
#2,550 of 2,830 medications looked up here in the last 7 days
Position among everything looked up on this site, not a measure of how commonly either one is used or how important it is. A supplement can climb this list because of a news story. It counts every request to the page, automated ones included, and nothing here identifies anyone.
Where does our data come from?
- Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
- Citation library: 103,510 references behind our interaction content, 65,311 of them resolved to verified PubMed/DOI sources. See every Glycomacropeptide reference on this page ↓
- Freshness: we automatically re-check this combination every week — this pair was last verified September 20, 2026. The Glycomacropeptide and Verteporfin records this page draws on were last updated July 10, 2026.
- What “no known interaction” means: no documented interaction in the sources above — not a guarantee of safety. Supplements are studied far less than prescription drugs, so we say exactly what the evidence supports, and nothing more.
About Glycomacropeptide
What is Glycomacropeptide?
- Phenylketonuria (PKU) nutrition
- Protein source low in phenylalanine
- Gut and digestive health
- Prebiotic support
- Appetite and satiety
Glycomacropeptide (GMP) is a milk-derived protein fragment best known as a low-phenylalanine protein source used in medical foods for people with phenylketonuria (PKU). It is also being studied for gut health and appetite, but evidence for most non-PKU uses is still limited. Talk to your doctor or dietitian before using GMP products, especially if you have a metabolic condition.
Peptide derived from milk casein (whey-based) · Medical foods, protein powders, capsules, ready-to-drink formulas
An interaction check asks whether these two react with each other — it does not ask whether Glycomacropeptide is a good idea for someone in your situation. Here is what our Glycomacropeptide record says about it on its own.
Glycomacropeptide: dosing
There is no single standardized dose of glycomacropeptide for general use. The right amount depends on why it is being used. For PKU, the amount is carefully calculated by a metabolic dietitian based on a person's protein needs and phenylalanine limits.For protein powders and other supplements, follow the directions on the product label. Avoid taking more than the label suggests.
From our Glycomacropeptide monograph — the full record covers uses, side effects and every documented interaction.
About Verteporfin Injection
What Is Verteporfin Injection Used For?
Brand name: Visudyne
Visudyne (verteporfin for injection) is used to treat a specific type of abnormal blood vessel growth under the retina called predominantly classic subfoveal choroidal neovascularization (CNV) — new, leaky vessels that form beneath the central part of the retina. It is approved for three underlying causes of this condition.
Visudyne is indicated when CNV is caused by age-related macular degeneration (AMD), pathologic myopia (severe nearsightedness that damages the eye), or presumed ocular histoplasmosis (an eye condition linked to a fungal infection). It is not indicated for the predominantly occult (hidden) form of CNV, where there is not enough evidence to support its use.
Other Drugs & Glycomacropeptide
Browse every other medication we’ve checked against Glycomacropeptide — both the ones with a known interaction and the ones without. Select any drug for the full detail.
No drugs match “”.
No interaction 2,829 drugs checked — show the list
We also checked Glycomacropeptide against these medications and found no known interaction in our sources. Open any page to confirm.
- Apixaban ›
- Levothyroxine ›
- Amlodipine ›
- Methylphenidate ›
- Warfarin ›
- Sertraline ›
- Testosterone ›
- Losartan Potassium ›
- Ivermectin ›
- Aspirin ›
- Abemaciclib ›
- Acetaminophen ›
- Metoprolol ›
- Rosuvastatin ›
- Rivaroxaban ›
- Escitalopram ›
- Clopidogrel ›
- Atorvastatin ›
- Docusate ›
- Tadalafil ›
- Tirzepatide ›
- Methamphetamine ›
- Ibuprofen ›
- Warfarin Sodium ›
- Valacyclovir ›
- Hydroxyurea ›
- Sumatriptan ›
- Semaglutide ›
- Prednisone ›
- Lisdexamfetamine ›
- Propranolol ›
- Amitriptyline ›
- Metformin ›
- Amoxicillin ›
- Lisinopril ›
- Isotretinoin ›
- Amlodipine Besylate ›
- Methotrexate ›
- Bendamustine ›
- Bupropion ›
- Amphetamine ›
- Doxycycline ›
- Fluoxetine ›
- Azithromycin ›
- Acyclovir ›
- Pregabalin ›
- Lamotrigine ›
- Dextroamphetamine ›
- Gabapentin ›
- Acetaminophen, Codeine ›
- Levothyroxine, Liothyronine ›
- Clonazepam ›
- Quetiapine ›
- Naproxen ›
- Omeprazole ›
- Letrozole ›
- Duloxetine ›
- Methylene Blue ›
- Buspirone ›
- Citalopram ›
Showing the 60 most looked-up of 2,829 medications checked with no known interaction — see the full Glycomacropeptide list.
Glycomacropeptide References
The 12 references that drive our Glycomacropeptide monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.
- van Calcar SC, MacLeod EL, Gleason ST, et al. Improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acids. Am J Clin Nutr 2009;89(4):1068-1077. PubMed
- Keogh, J. B. and Clifton, P. The effect of meal replacements high in glycomacropeptide on weight loss and markers of cardiovascular disease risk. Am J Clin Nutr 2008;87(6):1602-1605. DOI
- Dalbeth N, Ames R, Gamble GD, et al. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial. Ann Rheum Dis. 2012;71(6):929-34. PubMed
- Ney DM, Stroup BM, Clayton MK, et al. Glycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial. Am J Clin Nutr. 2016;104(2):334-45. PubMed
- Daly A, Evans S, Chahal S, et al. Glycomacropeptide: long-term use and impact on blood phenylalanine, growth and nutritional status in children with PKU. Orphanet J Rare Dis 2019;14(1):44. doi: 10.1186/s13023-019-1011-y. PubMed
- Tiele A, Daly A, Hattersley J, et al. Investigation of paediatric PKU breath malodour, comparing glycomacropeptide with phenylalanine free L-amino acid supplements. J Breath Res 2019;14(1):016001. doi: 10.1088/1752-7163/ab4097. PubMed
- Larsen ER, Juel A, Jensen E, Hollyer TR, Wegener G. Dietary supplementation with casein glycomacropeptide, leucine and tryptophan reduces plasma amino acid levels in men. Acta Neuropsychiatr 2022;34(2):69-76. PubMed
- Delsoglio M, Capener R, MacDonald A, et al. Evaluation of a New 'Mix-In' Style Glycomacropeptide-Based Protein Substitute for Food and Drinks in Patients with Phenylketonuria and Tyrosinemia. Nutrients 2023;15(16):3598. PubMed
- Delsoglio M, Capener R, MacDonald A, et al. Evaluation of a New Glycomacropeptide-Based Protein Substitute in Powdered and Liquid Format in Patients with PKU. Nutrients 2023;15(16):3580. PubMed
- Daly A, Högler W, Crabtree N, et al. A Three-Year Longitudinal Study Comparing Bone Mass, Density, and Geometry Measured by DXA, pQCT, and Bone Turnover Markers in Children with PKU Taking L-Amino Acid or Glycomacropeptide Protein Substitutes. Nutrients 2 PubMed
- Pena MJ, Pinto A, de Almeida MF, et al. Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective. Orphanet J Rare Dis 2021;16(1):84. PubMed
- Daly A, Högler W, Crabtree N, et al. Growth and Body Composition in PKU Children-A Three-Year Prospective Study Comparing the Effects of L-Amino Acid to Glycomacropeptide Protein Substitutes. Nutrients 2021;13(4):1323. PubMed
Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is written and reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.
Taking Glycomacropeptide and Verteporfin Together: Common Questions
Is it safe to take Glycomacropeptide with Verteporfin?
Do Glycomacropeptide and Verteporfin have any of the same side effects?
Does Verteporfin interact with any supplements?
Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy
Keep Exploring
Still Have a Question About Verteporfin and Glycomacropeptide?
Our pharmacists answer your medication & supplement questions — free.
This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.